Biotech Deals, Cuts, and Approvals
Kilder
- Endpoints: GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront
- Pharmaceutical-technology: GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal - pharmaceutical-technology.com
- Kalkinemedia: HUTCHMED (NASDAQ: HCM) Licenses HMPL-A830 to GSK with $110M Upfront Payment and $1.185B in Milestones - Kalkine Media
- BioSpace: TScan cuts 75% of workforce while shifting focus to solid tumor program
- Biopharminternational: TScan Therapeutics Cuts 75% of Staff, Pivots to In Vivo TCR-T for Solid Tumors - BioPharm International
- STAT: STAT+: Seattle scientists launch $95 million AI biology effort
- STAT: Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder - STAT
- STAT: ‘Tactical athletes’ get new guidance for cardiovascular fitness - STAT
- Endpoints: Superluminal secures $60M for Phase 1 of genetic obesity drug
- Raps: Recon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drug - RAPS
- BioPharma Dive: An AI drug specialist zeroes in on rare forms of obesity - biopharmadive.com
- STAT: STAT+: Abivax has still not been acquired. What’s going on?
- BioSpace: Biopharma needs more data scientists. Who's getting hired?
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.